Healthcare

Relay Therapeutics is a precision oncology biotech built around targeted drug design and clinically important mutation-driven cancers. Its appeal lies in a differentiated research platform, advancing lead programs, and a balance sheet with limited debt despite ongoing cash burn.

Arcus Biosciences is a clinical-stage cancer biotech built around immunotherapy combinations and backed by a major Gilead partnership. The appeal rests on a broad oncology pipeline and meaningful late-stage catalysts that could reshape its financial profile.

Regencell Bioscience is pursuing traditional Chinese medicine-based treatments for ADHD and autism-related conditions. The medical need is large, expenses have been reduced, and future value depends on turning a differentiated concept into credible clinical and commercial progress.

Privia Health helps physician practices manage operations, payer relationships, and value-based care through a scalable platform. Revenue growth has remained strong, leverage is minimal, and expanding provider networks give the company a credible path to greater long-term earnings power.

Pulse Biosciences is building a differentiated pulsed-field ablation platform aimed at large medical markets, especially electrophysiology. The appeal comes from real category growth and multi-use technology potential, even though commercialization is still at an early stage.

Precigen is a development-stage biotech building gene and cell therapies, with its appeal centered on advanced oncology programs and recent momentum. The upside case depends on clinical progress turning a small revenue base into a more durable commercial platform.

Parabilis Medicines is a pre-revenue biotech centered on turning research spending into future drug assets. The appeal lies in pipeline-driven upside, a debt-light balance sheet, and a strategy focused on development milestones that could reshape how the company is valued.